Keros Therapeutics (KROS) Competitors $15.76 +0.01 (+0.03%) As of 01:49 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock KROS vs. ALVO, TARS, CPRX, CGON, IBRX, IDYA, OCUL, DNLI, CNTA, and MLYSShould you be buying Keros Therapeutics stock or one of its competitors? The main competitors of Keros Therapeutics include Alvotech (ALVO), Tarsus Pharmaceuticals (TARS), Catalyst Pharmaceuticals (CPRX), CG Oncology (CGON), ImmunityBio (IBRX), IDEAYA Biosciences (IDYA), Ocular Therapeutix (OCUL), Denali Therapeutics (DNLI), Centessa Pharmaceuticals (CNTA), and Mineralys Therapeutics (MLYS). These companies are all part of the "pharmaceutical products" industry. Keros Therapeutics vs. Its Competitors Alvotech Tarsus Pharmaceuticals Catalyst Pharmaceuticals CG Oncology ImmunityBio IDEAYA Biosciences Ocular Therapeutix Denali Therapeutics Centessa Pharmaceuticals Mineralys Therapeutics Alvotech (NASDAQ:ALVO) and Keros Therapeutics (NASDAQ:KROS) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, dividends, risk, profitability, valuation and earnings. Which has more volatility & risk, ALVO or KROS? Alvotech has a beta of 0.1, indicating that its stock price is 90% less volatile than the S&P 500. Comparatively, Keros Therapeutics has a beta of 1.06, indicating that its stock price is 6% more volatile than the S&P 500. Do insiders & institutionals have more ownership in ALVO or KROS? 71.6% of Keros Therapeutics shares are owned by institutional investors. 0.5% of Alvotech shares are owned by insiders. Comparatively, 20.6% of Keros Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Do analysts rate ALVO or KROS? Alvotech presently has a consensus price target of $14.00, indicating a potential upside of 74.67%. Keros Therapeutics has a consensus price target of $30.00, indicating a potential upside of 90.29%. Given Keros Therapeutics' higher probable upside, analysts clearly believe Keros Therapeutics is more favorable than Alvotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alvotech 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Keros Therapeutics 0 Sell rating(s) 7 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.50 Does the media refer more to ALVO or KROS? In the previous week, Keros Therapeutics had 3 more articles in the media than Alvotech. MarketBeat recorded 8 mentions for Keros Therapeutics and 5 mentions for Alvotech. Alvotech's average media sentiment score of 1.39 beat Keros Therapeutics' score of 1.19 indicating that Alvotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alvotech 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Keros Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable valuation & earnings, ALVO or KROS? Keros Therapeutics has lower revenue, but higher earnings than Alvotech. Alvotech is trading at a lower price-to-earnings ratio than Keros Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlvotech$491.98M4.91-$231.86M$0.2334.85Keros Therapeutics$3.55M180.39-$187.35M$0.3150.85 Is ALVO or KROS more profitable? Alvotech has a net margin of 11.26% compared to Keros Therapeutics' net margin of 8.06%. Keros Therapeutics' return on equity of 2.96% beat Alvotech's return on equity.Company Net Margins Return on Equity Return on Assets Alvotech11.26% -38.36% 9.28% Keros Therapeutics 8.06%2.96%2.74% SummaryKeros Therapeutics beats Alvotech on 11 of the 15 factors compared between the two stocks. Get Keros Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KROS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KROS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KROS vs. The Competition Export to ExcelMetricKeros TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$640.62M$3.14B$5.80B$10.16BDividend YieldN/A2.32%5.69%4.61%P/E Ratio50.8821.3374.6226.00Price / Sales180.39300.92468.1791.50Price / CashN/A45.3337.0859.91Price / Book1.129.5912.156.30Net Income-$187.35M-$53.32M$3.28B$270.75M7 Day Performance1.12%0.37%1.13%3.33%1 Month Performance14.99%9.01%7.44%6.49%1 Year Performance-72.05%12.82%63.14%28.08% Keros Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KROSKeros Therapeutics3.4786 of 5 stars$15.77+0.0%$30.00+90.3%-71.2%$640.62M$3.55M50.88100Positive NewsALVOAlvotech3.2787 of 5 stars$8.05+1.2%$14.00+74.0%-25.2%$2.43B$491.98M34.981,032Positive NewsShort Interest ↓TARSTarsus Pharmaceuticals2.7656 of 5 stars$57.18-0.9%$66.67+16.6%+63.1%$2.41B$295.52M-24.5250Positive NewsInsider TradeCPRXCatalyst Pharmaceuticals4.917 of 5 stars$19.65-0.7%$33.20+69.0%+4.1%$2.40B$491.73M11.9180Insider TradeCGONCG Oncology2.1994 of 5 stars$30.82+7.5%$54.30+76.2%-9.2%$2.35B$551K-17.4161IBRXImmunityBio2.516 of 5 stars$2.39+0.6%$10.75+350.7%-28.5%$2.25B$14.74M-4.97590Analyst ForecastIDYAIDEAYA Biosciences4.002 of 5 stars$25.58-0.7%$45.77+79.0%-31.1%$2.25B$7M-6.7680Analyst ForecastAnalyst RevisionOCULOcular Therapeutix3.9381 of 5 stars$12.62-2.5%$17.20+36.3%+51.3%$2.20B$63.72M-9.88230DNLIDenali Therapeutics4.3906 of 5 stars$14.95-2.3%$33.62+124.8%-45.3%$2.19B$330.53M-5.34430Positive NewsCNTACentessa Pharmaceuticals3.2442 of 5 stars$15.86-0.3%$31.45+98.4%+64.9%$2.12B$6.85M-8.86200Insider TradeMLYSMineralys Therapeutics2.9402 of 5 stars$31.90+9.1%$36.60+14.7%+219.2%$2.11BN/A-8.9628Analyst Forecast Related Companies and Tools Related Companies Alvotech Alternatives Tarsus Pharmaceuticals Alternatives Catalyst Pharmaceuticals Alternatives CG Oncology Alternatives ImmunityBio Alternatives IDEAYA Biosciences Alternatives Ocular Therapeutix Alternatives Denali Therapeutics Alternatives Centessa Pharmaceuticals Alternatives Mineralys Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KROS) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredGENIUS Act: The Plot to Seize Your Cash?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Keros Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Keros Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
